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disease/susceptibility genes. Alternatively, if the case-controlEvidence for genetic factors in the development and progres-
study design is employed to identify associations between par-sion of IgA nephropathy.
ticular candidate genes or markers and the development ofBackground. IgA nephropathy (IgAN) is the most common
IgAN, spurious associations caused by the effects of populationglomerulonephritis in the world among patients undergoing
stratification should be ruled out by confirming the findingsrenal biopsy. Once considered a relatively benign condition,
using powerful and sensitive family-based methodologies suchlongitudinal follow-up studies have revealed that in fact 9 to
as the transmission/dysequilibrium test (TDT).50% of patients progress to end-stage renal disease within
20 years of disease onset. In the three decades since its first
description by Jean Berger and Nicole Hinglais, clinical, epide-
miologic, and immunologic studies of the pathogenesis of pri- Over three decades have passed since Jean Berger andmary (idiopathic) mesangial glomerulonephritis with predomi-
Nicole Hinglais first reported the immunofluorescent de-nant IgA deposits have characterized the features of IgAN as
tection of IgA and IgG mesangial deposits in kidneya distinct glomerular disease entity. However, the basic molecu-
lar mechanism(s) underlying abnormal IgA deposition in the biopsy specimens from patients with persistent hematuria
mesangium with ensuing extracellular matrix expansion and and proteinuria [1]. They subsequently proposed primary
mesangial cell proliferation remains poorly understood. The (idiopathic) mesangial glomerulonephritis with predom-task of elucidating the molecular basis of IgAN is made espe-
inantly IgA deposits as a distinct entity [2]. The twocially challenging by the fact that both environmental and ge-
decades following Berger’s seminal articles can be char-netic components likely contribute to the development and
progression of IgAN. acterized as a period of descriptive study and growing
Methods and Results. We review here the evidence for ge- appreciation of the unique immunopathologic features
netic factors in the development and progression of IgAN, of both primary IgA nephropathy (pIgAN), the closely
including a reappraisal of earlier conflicting results from small
linked systemic illness Henoch-Scho¨nlein purpura (HSP),immunogenetic case-control studies, the evidence for racial
and a broad spectrum of glomerulopathies characterizeddifferences in the prevalence of IgAN, a detailed summary of
by IgA deposition such as that observed in lupus nephri-all reported occurrences of familial IgAN worldwide, and an
exhaustive review of new insights gained through the study tis and hepatic glomerulosclerosis [reviewed in 3, 4]. This
of two murine models of hereditary IgAN: the ddY and the has prompted the widely held notion of IgAN as a syn-
uteroglobin-deficient mouse. drome and has led to the clinicopathologic distinctionConclusions. With the development of powerful molecular
between primary and secondary forms of disease associ-genetic approaches to the study of both Mendelian and com-
ated with IgA mesangial deposits [reviewed in 2, 3, 5–7].plex human genetic diseases, and the successful efforts of inves-
tigators to identify and clinically characterize large IgAN multi- pIgAN, defined as predominant IgA mesangial deposits
plex families, we propose that genetic analysis of familial IgAN in the absence of clinical or laboratory evidence of other
is the most promising approach to the identification of IgAN associated systemic disease, has also been proposed to
include at least two distinct clinical entities (those with
and without macroscopic hematuria) [5, 7].Key words: heredity, IgAN, familial nephropathy, glomerulonephritis,
chronic renal failure, hematuria. During this same time period, demographic studies
revealed that IgAN was the most common glomerulone-Received for publication July 21, 1999
phritis in the world among patients undergoing renaland in revised form October 15, 1999
Accepted for publication December 9, 1999 biopsy [8–11]; the prevalence has been observed to be as
great as 50% of all glomerular diseases in Asia, especiallyÓ 2000 by the International Society of Nephrology
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among the Japanese. The clinical significance of this dis- Bw35 [26, 27]. A strong association between benign
(nonprogressive) IgAN and the HLA-DR4 antigen wasorder is further emphasized by its natural history. Longi-
tudinal follow-up studies of biopsy-proven cases of IgAN first reported in a Japanese cohort of 103 adult patients
[28]. Although numerous independent groups have re-reveal that 9 to 50% of the patients progress to end-
stage renal disease (ESRD) within 20 years of disease ported these same results, neither Bw35 nor DR4 has
been consistently confirmed to be associated with pIgANonset [8–11]. Despite intensive efforts to elucidate the
pathogenesis of the IgA glomerulopathies, employing [reviewed in 22]. The explanation for the discrepancy
among these studies has been attributed to differencesboth immunologic and immunogenetic approaches, little
progress has been made in defining the precise molecular in policies governing diagnostic renal biopsy, the small
number of patients enrolled, racial differences that re-mechanism(s) of this common and clinically important
glomerular disease process [4, 12, 13]. While powerful flect the variation in genetic background of cohorts from
different countries, genetic heterogeneity of IgAN dis-molecular genetic approaches have been applied to the
study of both Mendelian and complex human genetic dis- ease/susceptibility genes, and the effect of environmental
factors on the expression of such genes (the genetic con-eases, leading to the identification of novel genes responsi-
ble for kidney diseases such as autosomal dominant poly- cept of epistasis) in different populations [22].
The observed inconsistencies have also raised the pos-cystic kidney disease [14–16], juvenile nephronophthisis
type I [17], and congenital nephrotic syndrome of the sibility that the genes encoding the HLA antigens act as
markers for a closely linked disease/susceptibility locus,Finnish type [18], progress has not been made in identi-
fying the genes involved in the IgA glomerulopathies. rather than being disease-causing genes themselves [21, 22].
This explanation appeared to gain initial support withThis review summarizes the evidence for genetic fac-
tors in the development and progression of the IgA glom- the introduction of molecular biological techniques for
determining MHC gene allelic variation through the anal-erulopathies. We begin with a reappraisal of earlier con-
flicting results from small case-control studies on the ysis of DNA restriction fragment length polymorphisms
(RFLPs) and the use of allele-specific oligonucleotiderole of immune response genes [centered on the major
histocompatibility complex (MHC) genes] in light of (ASO) hybridization probes. These techniques overcame
the limitations of traditional HLA typing methods andmore recent studies using high-resolution DNA genotyp-
ing, as well as important new reports of gene polymor- allowed investigators to distinguish definitively between
two or more alleles for a single MHC gene. The earliestphisms associated with IgAN disease progression. This
is followed by a critical examination of the evidence case-control study employing RFLP typing was performed
by Moore et al in 1990. These investigators initially dem-for racial differences in the prevalence of IgAN and a
detailed summary of all reported occurrences of familial onstrated an association between the MHC class II allelic
polymorphism HLA-DQB1 and pIgAN among BritishIgAN worldwide. Finally, we review new insights gained
about the pathogenesis of IgAN through the ongoing patients (Table 1) [29]. This finding led them to propose
that, since the IgA antibody response is T-cell depen-study of two murine models of hereditary IgAN: the
ddY and the uteroglobin (UG)-deficient mouse. The role dent, the MHC class II products encoded by the DP,
DQ, and DR genes might play a crucial role in the presen-of environmental factors in the etiology of IgAN is also
discussed in the specific context of their impact on ge- tation of processed antigen to specific T-cells. The appar-
ent DQB1 association could be of pathogenetic signifi-netic approaches to disease gene mapping [19].
cance in pIgAN by determining the responder status to
either native or foreign antigen. This hypothesis possessed
CANDIDATE DISEASE GENE
both biologic plausibility and experimental support from
POLYMORPHISM STUDIES
the work of other investigators. Several autoimmune
Role of MHC class II gene polymorphisms in pIgAN diseases, including rheumatoid arthritis (RA) and insu-
lin-dependent diabetes mellitus (IDDM), have also beenThe earliest studies of the role of genetic factors in
pIgAN were reported in the mid-1970s. These studies linked to allelic polymorphisms of the DQB1 product
[reviewed in 29, 30]. However, the early studies of Moorefocused on the association between specific HLA anti-
gens encoded by the human MHC locus and the develop- et al relied on the presence of a combination of the Taq I
RFLP fragments T2 (2.0 kb) and T6 (6.0 kg) to definement of pIgAN, and defined allelic variation (the HLA
genotype) by traditional serologic and cellular tech- a disease-associated DQB1 polymorphism, a technique
that was subsequently revealed by polymerase chain re-niques that require the expression of membrane-bound
HLA proteins on lymphocytes [reviewed in 20–22]. A action (PCR)-RFLP (discussed later in this article) to be
unable to distinguish between multiple allelic variationsstrong association between pIgAN and the HLA Bw35
antigen was initially reported in small Australian and at the HLA-DQB1 locus. For example, the T2 RFLP iden-
tifies but cannot distinguish between the HLA-DQ*0302,French cohorts [23–25], and was supported by several
reports of twins with IgAN who shared the HLA-antigen *0303, and *0402 alleles [31]. Although a subsequent study
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Table 1. Genotypic studies of HLA-DQ alleles and their association with pIgAN
Patients Controls
Follow-up Subgroup
Ref. Year Race Ethnicity years Methods HLA comparisons P value OR% frequency
[32] 1990 Caucasian British 98 (50) 94 (16) RFLP DQB1 (T2/T6) ,0.0001 5.3
[33] 1991 Caucasian British 35 (71) 1103 (28) RFLP/ASO DQB1*0301 ,0.001 6.4
[23] 1993 Caucasian Italian 73 (29) 63 (32) RFLP DQB1 (T2/T6) NS
Finnish 47 (28) 34 (35) DQB1 (T2/T6) NS
[25] 1993 Caucasian German 67 (43) 22 (23) RFLP DQA1*0101 ,0.05 2.6
[38] 1995 Caucasian Australian 70 230 RFLP DQA/DQB typinga NS
[42] 1991 Multiracial Italy
Turin 76 1108 PCR/ASO DQA1 (6 alleles) Sporadic NS
(Ethically DQB1 (7 alleles)a NS
21 matched DQA1/DQB1 Familial NS
Pavia 94 controls) DQA1/DQB1 Sporadic NS
Japan 39 (18) ? (38) DQB1*0601 Sporadic ,0.05 5.18b
39 (13) ? (30) DQB1*0301 ,0.025 4.36b
[39] 1994 Caucasian American 64 75 PCR-RFLP DQB1 (17 alleles)a NS
[40] 1995 Caucasian French 58 (26) 150 (16) PCR-RFLP DQB1*0301 All Pts vs. control NS
? 21 (62) 150 (29) Progressors vs.
controls ,0.0007 5.85
? 21 (62) 37 (35) Progressors vs.
non-progressors ? 2.89
[36] 1995 Caucasian French 62 170 PCR-RFLP DQB1 (7 alleles) NS
[35] 1996 Caucasian British 105 111 PCR-RFLP DQB1 (14 alleles)a NS
Italian 71 63 NS
Finnish 48 41 NS
[41] 1996 Asian Korean 30 46 PCR-RFLP DQB1 (10 alleles)a NS
30 (80) 46 (50) DQA1*0301 0.04 4.0
[34] 1994 Asian Chinese 79 104 PCR-RFLP DQB1 (6 alleles)a All Pts NS
79 (41) 104 (28) DQA2 U All Pts NS
$1 21 (67) 52 (27) DQA2 U Progressors vs.
non-progressors 0.0016 5.4
$1 21 (67) 104 (28) DQA2 U Progressors vs.
control ,0.0003 5.2
79 (33) 104 (20) DQA1*0201 All Pts NS
$1 21 (14) 52 (40) DQA1*0201 Progressors vs.
non-progressors 0.03 0.2
Abbreviations are: Ref., reference; HLA, human lymphocyte antigen; RFLP, restriction fragment length polymorphism; ASO, allele-specific oligonucleotide; OR,
odds ratio; Pts, patients.
aGenotyping panel included the DQB1*0301 allele
bChi-square test
employing higher resolution RFLP/ASO genotyping of of follow-up and adequate statistical analysis for the com-
parison of progressors versus nonprogressors was not pro-British patients confirmed that the specific allele HLA-
DQB1*0301 was strongly associated with pIgAN [32], vided, found an association between DQB1*0301 and dis-
ease progression [36]. All six additional case-control studiesthe follow-up report of Moore failed to find any associa-
tion between HLA-DQB1 and IgAN in Italian and Finn- reported to date using standardized PCR-RFLP HLA
genotyping [35–41] failed to find an association betweenish patients [21]. Two additional RFLP studies in Ger-
man and Australian patients [20, 33] also failed to find a any allele at the DQB1 locus (including DQB1*0301)
and the development or progression of pIgAN in multi-significant association at the HLA-DQB1 locus (Table 1).
With introduction of the PCR using sequence-specific ple racial and ethnic groups (lower half of Table 1). In
one Japanese cohort, the DQB1*0601 and *0301 allelesprimers followed by subsequent restriction enzyme diges-
tion (PCR-RFLP), HLA genotyping methods achieved the were reported to be less frequent (that is, protective
for IgAN) among patients with pIgAN compared withability to discriminate up to 16 distinct alleles at the HLA-
DQB1 locus [34]. When Fennessy et al repeated the controls [37]. Finally, in an analysis of 21 Italian patients
belonging to six families from Turin (familial IgAN), nogenotyping of British, Italian, and Finnish patients using
PCR-RFLP to examine the association between pIgAN association with any HLA allele was observed (including
HLA-DQB1*0301) [37]. Similarly, PCR-RFLP genotyp-and 14 distinct DQB1 alleles (including DQB1*0301), as
well as 8 distinct DQA1 alleles, no consistent association ing of 26 affected members belonging to 10 families with
ancestral roots in the Valsaviore valley in Northern Italyof any DQ alleles was apparent in any of the populations
studied (including the British patients) [35]. Only a small and comparison to either healthy family members, pa-
tients with sporadic pIgAN, or healthy ethnically matchedstudy of French Caucasian patients, in which the length
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controls found no compelling evidence for involvement Role of angiotensin-converting enzyme (ACE) gene
of the HLA system in the pathogenesis of IgAN in af- polymorphisms in the progression of pIgAN
fected family members [42]. Increased production or activity of angiotensin II
Thus, despite intriguing early reports of a strong associa- (Ang II) and decreased levels of bradykinin have been
tion between the HLA system and pIgAN, case-control hypothesized to play a detrimental role in the glomerular
studies in the past decade, employing high-resolution response to injury. The proposed pathophysiology is me-
HLA genotyping methodologies, demonstrate rather diated through adverse intraglomerular hemodynamic
consistently that at least among Caucasian patients of mechanisms [47, 48], promotion of inappropriate glo-
multiple ethnic backgrounds with either sporadic or fa- merular hypertrophy and sclerosis [49], and/or the prolif-
milial IgAN, allelic variation of HLA genes in the MHC erative effects of increased Ang II and decreased brady-
class II region does not appear to be associated with the kinin on tubular, mesangial, and smooth muscle cells
development of pIgAN. These findings differ from those [50, 51]. Following the discovery of an insertion/deletion
in Asian patients, in which several HLA-DQA alleles polymorphism in intron 16 of the human ACE gene, which
have been reported to be either associated with the oc- accounts for half of the variation in serum ACE levels
currence of pIgAN in Korean patients [41], or associated in a Caucasian study cohort [52], and the report of strong
with disease progression (DQA2 U associated with pro- associations between the D allele and common clinical
gression, DQA*0201 associated with benign course) in conditions such as cardiovascular disease (myocardial in-
Chinese patients (Table 1) [40]. These small isolated farction, left ventricular hypertrophy, and hypertension)
case-control studies are suggestive, but require confir- [reviewed in 53], end-organ complications of diabetes
mation by prospective studies of larger cohorts or by the mellitus (diabetic retinopathy and nephropathy) [reviewed
genetic analysis of familial IgAN (discussed later in this in 54], and progression of renal disease (glomerular dis-
article) before any conclusions can be drawn regarding ease, tubulointerstitial disease, polycystic kidney dis-
the role of HLA gene polymorphisms in the pathogenesis ease) [55–57], eight major studies have explored the asso-
and/or progression of pIgAN in different ethnic groups.
ciation between the ACE gene insertion/deletion (I/D)
polymorphism and the development and/or progressionRole of T-cell receptor (TCR) a and b chain gene
of pIgAN [58–65]. Details of the design and relevantpolymorphisms in pIgAN
findings from these studies are summarized in Table 2Hyperactivity of T cells and high serum levels of T-cell–
and are critically evaluated later in this article.derived cytokines such as interleukin-2 (IL-2) are charac-
All but one of these studies employed a combinationteristic of pIgAN [43, 44]. This has prompted several
of the case-control design (to identify an association be-investigators to examine the association between TCR
tween ACE gene polymorphisms and the developmentgene polymorphisms and the development and/or progres-
of disease) and the retrospective cohort design (to iden-sion of IgAN. A case-control study of the TCR Cb poly-
tify an association between ACE gene polymorphismsmorphism determined by RFLP analysis of Bgl II 10.0/9.2
and the progression of disease). The exception is a clini-kb fragments in 40 German patients with biopsy-proven
copathologic cross-sectional study [64]. These studies ex-pIgAN found no difference in allele frequencies com-
hibit important differences with regard to racial/ethnicpared with healthy controls [20]. However, a cohort study
study populations and differences in the length of follow-among Japanese patients with biopsy-proven pIgAN
up (range, 1 to $10 years), both of which may potentiallyfound that the 10 kb TCR Cb allele was associated with
lead to conflicting results. The relevance of race is bestdisease progression and higher maximal proteinuria after
exemplified by the finding that the association betweena follow-up of an average of 3.5 to 4.0 years [45]. A
the ACE DD genotype and higher ACE activity wassingle case-control study of TCR Ca gene polymorphisms
significant in French and American Caucasians (DD vs.determined by RFLP analysis of Taq I 7/2 kb fragments
II, P 5 0.0001) and a Japanese cohort [52, 66, 67], butin 53 Chinese patients with biopsy-proven pIgAN found
not in an African American cohort [66]. The relevancea significantly higher frequency of the 7 kb TCR Ca allele
of the length of clinical follow-up is raised by the factin patients versus healthy controls [60.3% (32 out of 53)
that although none of the studies found a significantvs. 38.8% (26 out of 67), P , 0.05] [46]. There was no
difference in ACE I/D genotype frequencies betweenassociation of any allele with either histologic grading
patients with pIgAN compared with healthy ethnicallyor disease progression in this cohort. These isolated stud-
matched controls, the majority of these studies also com-ies are suggestive of a role for germline polymophisms
pared ACE I/D genotype frequencies between cohortsof the unrearranged TCR Ca and Cb genes in the devel-
with stable renal function (defined variously as mainte-opment and progression of pIgAN, respectively. The
nance of creatinine #1.5 mg/dL or failure to exhibit aTCR genes should be considered candidate disease/sus-
doubling of creatinine) versus patients with progressiveceptibility loci and further evaluated in larger prospec-
tive studies or by the genetic analysis of familial IgAN. deterioration of renal function over time (including de-
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velopment of ESRD). An inadequate length of clinical other possible risk factors for disease progression such
as hypertension and/or heavy proteinuria at presentationobservation would tend to misclassify individuals with
the DD genotype, who may be destined to experience (Table 2). The ACE genotype was found to be an inde-
pendent risk factor for disease progression upon adjustingdisease progression, to the stable renal function group
(“observation bias”). An additional bias favoring the for blood pressure and proteinuria (incidence relative risk,
IRR 5 7.5, 95% CI, 1.3 to 44.9, P 5 0.027). In a relativelyunderrepresentation of patients with the DD genotype
among progressors is suggested by a recent meta-analy- large study by Pei et al, univariate analysis found no
association between ACE genotype frequencies and dis-sis, which supports an association of the D allele with
myocardial infarction [65]. Since none of the case-control ease progression or proteinuria in patients with pIgAN
[63]. Multivariate analysis, however, revealed an adversestudies in pIgAN patients reported the frequency of the
DD genotype as a function of the duration of deteriorat- influence on disease progression of the ACE DD geno-
type in patients with the concomitant angiotensinogening renal function or chronic dialysis, an “observation
bias” might eliminate those patients at exceedingly high MM genotype (P 5 0.008; discussed later in this article),
after adjusting for age and serum creatinine at presenta-risk for death caused by cardiovascular disease (“com-
peting risks”) or for death caused by the combination tion. Mean arterial blood pressure at presentation or
at last follow-up was not found to be an independentof cardiovascular disease and chronic uremia (“additive
risks”) from consideration in the statistical analysis. predictor of disease progression in this study. In a rela-
tively large cross-sectional study comparing morphologicAnother important limitation of the majority of these
studies is evident in the comparison of ACE I/D genotype findings and urinary protein excretion at the time of
biopsy with ACE genotype in children (age #15), Ta-frequencies between progressors and nonprogressors.
Few studies attempted to account for the effects of inde- naka et al reported that the ID/DD genotypes were asso-
ciated with indices of chronic injury such as capsularpendent poor prognostic indicators for disease progres-
sion such as hypertension and heavy proteinuria (nor adhesions, glomerulosclerosis, and higher urinary pro-
tein excretion [64]. They concluded that the ACE genethe influence of the ACE D allele in subsets defined
by age, sex, race, tobacco use, or presence of familial ID/DD genotypes are associated with pathologic param-
eters of known prognostic significance in pIgAN. Finally,hyperlipidemia) by multivariate analysis. Inadequate
sample size may also contribute to inconsistencies in the study by Stratta et al adjusted for a number of clinical
covariates potentially associated with disease progressionthe results of these studies, particularly if several major
susceptibility loci are hypothesized to determine a multi- such as hypertension, heavy proteinuria (.3 g/day), and
ACE inhibitor therapy, and found a strong associationfactorial event such as disease progression [65]. A final
critical difference in study methodology relates to the between the DD genotype and 5- and 10-year renal sur-
vival rates [65]. There were no significant differencesuse of an insertion-specific PCR primer pair [68] in all
studies beginning in 1996 (the four most recent studies), between the ACE genotype subgroups in age, sex, blood
pressure, proteinuria, ACE inhibitor therapy, and renalwhich eliminated the possibility of preferential amplifi-
cation of the D allele. Thus, in earlier studies, ID hetero- histopathologic lesions at the time of biopsy. The ACE
DD genotype was found to be an independent risk factorzygotes may have been mistyped as D homozygotes,
introducing another source of observation bias. In gen- for decreased renal survival (HR 5 3.6; 95% CI, 1.1 to
12); the coexistence of heavy proteinuria increased theeral, the use of insertion-specific PCR primers would be
expected to improve the accuracy of genotyping and the risk even further (HR 5 9.16; 95% CI, 1.8 to 15.7).
Overall, the type of methodologic weaknesses inher-validity of the study results. Given the potential for bias
inherent in the earlier studies that predate the use of ent in these studies, such as failure to account for in-
creased mortality associated with the ACE DD genotypeinsertion-specific PCR primers, it is not unexpected that
two studies reported association [58, 59], while two stud- caused by competing risks, would tend to bias in favor
of the null hypothesis for an association between theies reported no association [60, 61], between ACE I/D
genotype and disease progression (Table 2). The remain- ACE D allele and disease progression in pIgAN. The
finding of a positive association in the majority of recentder of the discussion focuses on a critical appraisal of
the four most recent studies [62–65]. studies that employed improved genotyping methodolo-
gies and more strict stratification of patients into sub-The retrospective cohort study by Hunley et al first
examined the association between ACE I/D genotype groups with well-defined covariates of disease progres-
sion strongly supports the association between ACE genefrequencies and disease progression in a small group of
patients with pIgAN who presented with normal serum D allele and the progression of established pIgAN. Large
prospective studies of well-defined ethnic/racial cohorts,creatinine at the time of biopsy [62]. They found a trend
toward increased frequency of the DD genotype among however, with sufficient follow-up, adjustment for drop-
out because of death from competing risks such as car-progressors (P 5 0.057), which became significant (P 5
0.009) when they excluded patients who presented with diac disease, and randomization according to both treat-
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ment with ACE inhibitors (and other therapeutic agents) servation that deserves further investigation and con-
firmation.and the ACE genotype, are required to implicate fully
a role for ACE I/D polymorphisms in the progression
of IgAN.
RACIAL DIFFERENCES
Role of other renin-angiotensin system gene Incidence and prevalence figures for pIgAN suggest
polymorphisms in the progression of pIgAN that it is the most common glomerulonephritis worldwide
[8–11]. The true population incidence rates for pIgANPolymorphic variants of genes encoding two additional
are unknown since definitive diagnosis is dependent oncomponents of the renin-angiotensin system, angioten-
policies governing renal biopsy, which vary considerablysinogen, and Ang II type 1 receptor (ATR1) have been
from country to country. For example, the high incidencereported to be associated with cardiovascular disease
figures reported for Singaporean Asian males undergoing[69, 70]. A study from the Toronto Glomerulonephritis
renal biopsy likely reflect the practice of mandatory rou-Registry tested the hypothesis that the frequencies of
tine screening for urinary abnormalities of all army re-polymorphic variants in the angiotensinogen gene (AGT
cruits [71, 72]. In addition, a large proportion of clinicallyM235!T), the ATR1 gene (A1166!C), and the ACE gene
silent and undetected IgAN likely exists, as suggested(I/D), may modify renal disease progression in pIgAN
by a control necropsy study of 200 consecutive patients[63]. Genotype frequencies for each gene were consistent
who died of traumatic injuries and had no clinical historywith Hardy–Weinberg equilibrium in 168 Caucasian pa-
of renal disease or other organic disease discovered attients and were similar to those of 100 Caucasian control
the time of necropsy [73]. Mesangial IgA was the pre-subjects. However, multivariate analysis revealed an as-
dominant immunoglobulin found in 4% of these appar-sociation between the AGT MT/TT genotype (compared
ently “normal” cases from the general population (5 outwith MM) and a progressive decline in renal function
of 153 males and 3 out of 47 females). Racial differences[odds ratio (OR) 5 2.86, P , 0.001], independent of the
in disease incidence, which have been advanced in supporteffects of hypertension. This result would implicate the
of a genetic basis for susceptibility to the development ofAGT T235 variant as a risk factor for disease progression
hypertensive nephrosclerosis and diabetic nephropathyin pIgAN. A large proportion of the subjects in the
among African Americans [74], remain largely unknownToronto study were treated with antihypertensive medi-
for pIgAN. The one exception is a relatively low preva-cations at the time of diagnosis, thereby limiting the
lence of pIgAN and HSP reported for both African andability to detect an association between the AGT T235
American Blacks that cannot readily be accounted forvariant and hypertension. Thus, it remains possible that
by differences in the racial distribution of hospital admis-the adverse influence of this allelic variant is mediated
through a direct effect on blood pressure rather than sions or renal biopsies performed [75, 76]. These findings
through an independent effect on deterioration of renal provide indirect support for the existence of genetic fac-
function. This possibility is supported by an earlier study tors that determine susceptibility to the development of
that failed to find an association between the AGT T235 pIgAN.
variant and disease progression in a subset of patients
without clinical risk factors for progression (elevated cre-
FAMILIAL IgAN AND ASSOCIATEDatinine, hypertension, and heavy proteinuria) at the time
OVERLAP SYNDROMESof diagnosis [62]. Alternatively, the AGT T235 variant
The strongest evidence from human studies of a rolemay contribute to the progression of renal failure by
for genetic factors in the development and progressionits effects on intrarenal Ang II production, glomerular
of IgAN is provided by descriptive reports of familialhypertrophy, and tubular and mesangial cellular prolifer-
aggregations of pIgAN. Affected sib pairs and parent-ation and matrix deposition, as reviewed in the previous
child pairs have been reported from a multitude of ethnicsection. Finally, there remains the possibility that the
backgrounds (Table 3). In addition, one large extendedAGT T235 variant may simply be a marker in linkage
multiplex American family of Scottish, Irish, and Englishdisequilibrium with an as of yet unidentified neighboring
descent and a five-generation Australian Aboriginal fam-disease-progression gene [63].
ily have been studied in detail (Table 4). There is alsoAlthough univariate analysis failed to demonstrate an
reported familial aggregation in multiple, unrelated mul-association between ACE or ATR1 gene polymorphisms
tiplex American Zuni Indian families from New Mexicoand disease progression in the study of Pei et al, multivar-
and Northern Italian families from the Valsaviore valleyiate analysis revealed that the ACE DD genotype ad-
of the district of Brescia. Familial syndromes with otherversely affected disease progression only in patients with
primary features but having associated mesangial IgAthe AGT MM genotype (P 5 0.008; Table 2). This sug-
deposition as a clinical finding (overlap syndromes) havegests an interaction between specific allelic variants in
two components of the renin-angiotensin system, an ob- also been reported (Table 5).
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Table 3. Familial primary IgAN simplex kindreds
Ref. Year Relationship of affected probands Race Ethnicity Other affected family membersa
[29] 1978 HLA-identical brothers Caucasian Lebanese ND
[30] 1979 HLA-identical brothers Caucasian French ND
[79] 1980 HLA-unrelated siblings Caucasian Spain —
[80] 1981 HLA-unrelated father and son Caucasian Spain —
[81] 1984 HLA-DR4-related siblings Asian Japanese ND
[82] 1986 HLA-identical sisters Asian Japanese Father, sister with microhematuria
[83] 1988 HLA-identical brother Caucasian American —
[86] 1989 34 families with 2–3 affecteds Caucasian French —
[84] 1992 2 HLA-identical brothers, Caucasian Yugoslavian ND
1 HLA-unrelated brother
[85] 1996 Identical twin sisters Asian Japanese ND
[87] 1997 HLA-identical siblings Caucasian Turkish ND
HLA-unrelated brothers
HLA-unrelated siblings
ND is not determined.
aDisease status determined by screening urinalysis
Familial IgAN simplex kindreds ico in the United States [88]. A high inbreeding coeffi-
cient of 0.00797 has been estimated for this entire popula-Table 3 summarizes the reported cases of IgAN among
tion, compared with 0.00084 for the affected membersaffected sib pairs and parent-child pairs [26, 27, 77–85].
of the Kentucky kindred [86, 89]. Although 50% of theAlthough HLA identity among the sibs was advanced
Zuni ESRD population carried a diagnosis of diabetesas an argument in support of early case-control studies
mellitus up to 1989 [90], mesGN was found in 94% (50implicating specific HLA alleles such as DR4 in associa-
out of 53) of all Zuni Indian renal biopsies performedtion with IgAN, not all sib pairs were HLA identical, and
since 1971 [88]. An unusual feature of the mesGN amongno single HLA allele was reported to be associated with
the Zuni Indians is the marked familial clustering amongfamilial IgAN in these families. Furthermore, an HLA-
cases and the finding of disparate morphologic and im-unrelated brother of affected HLA-identical brothers
munofluorescence (IF) findings on renal biopsy amongfrom Yugoslavia also had IgAN [82].
affected family members (Table 4). Mesangial IgA de-
Familial IgAN multiplex kindreds posits were observed in 64% of 49 cases, usually in associ-
ation with electron dense mesangial deposits in well-To date, four large extended multiplex families of di-
established disease, whereas IgM and IgG deposits wereverse racial/ethnic backgrounds have been described that
present in 94 and 45% of cases, respectively; IgA deposi-exhibit familial clustering of IgAN with differing clinical
tion alone was not observed in any of the cases [88].features and at least two different putative genetic inheri-
A predominance of IgA deposition was associatedtance patterns (Table 4). Julian et al first described 14
with more severe clinical disease, but not with a greaterpatients with biopsy-proven IgAN from three potentially
incidence of renal failure in a Zuni biopsy case seriesrelated pedigrees of Scottish, Irish, and English descent
[91]. Of the three renal biopsies in family 2 (F-II), onlyfrom central and eastern Kentucky in the United States
one showed mesGN with deposition of IgA, IgG, and[86]. An additional 17 members of the extended pedigree
IgM, whereas the remainder showed typical focal seg-had clinical glomerulonephritis, and 6 had “chronic ne-
mental glomerulosclerosis (FSGS) without Ig deposition.phritis” noted on their death certificates. Assuming that
In contrast, of the 10 renal biopsies in F-V, 5 showedall 35 patients with evidence of renal disease in this family
mesGN with IgA deposition (with or without IgG and/orhad IgAN nephropathy, the presence of male-to-male
IgM), but cases of isolated IgG mesangial deposition andtransmission and an equal distribution of affected males
FSGS were also observed. The light microscopic findingsand females is consistent with the segregation of a simple
of either FSGS or crescents appeared to be associatedautosomal dominant (for example, monogenic) trait for
with the development of nephrotic syndrome and pro-IgAN in this kindred [87]. Notably, no single HLA haplo-
gression to ESRD. Isolated IgM mesangial deposits weretype was found to be associated with IgAN in this multi-
observed in affected members of F-I and F-VI. Nephroticplex family.
syndrome associated with either isolated IgG or IgMSegregation of an apparently autosomal dominant
mesangial deposits have been previously reported [92, 93].trait for an unusual variant of mesangial proliferative
Membranoproliferative GN (MPGN) was the biopsy find-glomerulonephritis (mesGN) has been observed among
the Zuni Indians, who comprise an isolated and highly ing in 3 Zuni patients in a reported biopsy series of 44
patients with nondiabetic renal disease, and was associ-consanguinous Pueblo community in western New Mex-
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Table 4. Familial IgAN multiplex kindreds
No. of No. of No. of Other biopsy M:F ratio Putative pattern of
Ref. Year affectedsa assessedb generations findingsc Race Ethnicity affectedsd inheritanced
[88] 1985 35:14:6 176 8 — Caucasian American 18:17 Autosomal dominant
[96] 1987 17:6 49 3 1 non-IgA mesGN, Aboriginal Australian 14:3 X-linked recessive
1 ?HTN/DM
[89] 1989 Six families Amerindians Zuni
F-I 8:2:1 23 5 1 IgM 4:5 Autosomal dominant
F-II 7:3:0 11 3 2 FSGS 4:3 Autosomal dominant
F-III 5:1:1 9 3 1 IgA/FSGS 3:3 Autosomal dominant
F-IV 3:2:1 11 4 2 Crescents 3:1 ?
F-V 31:10:9 66 4 1 normal, 20:20 Autosomal dominant
1 amyloid/DM,
2 IgG, 1 FSGS,
1 IgA/FSGS
F-VI 13:7:6 29 5 1 IgM, 2 FSGS, 7:12 ?
1 IgG/IgM/MGN
[45] 1990 10 families Caucasian Italian
F-I 5:3 16 3 4:1 X-linked recessive
F-II 8:5 44 7 7:1 X-linked recessive
F-III 5:2 47 12 3:2 ?
F-IV 6:4 55 11 5:1 X-linked recessive
F-V 2:2 8 2 2:0 ?
F-VI 3:2 5 2 2:1 ?
F-VII 3:2 5 2 3:0 ?
F-VIII 2:2 6 2 2:0 ?
F-IX 2:2 12 2 1:1 ?
F-X 3:2 23 4 2:1 ?
aBiopsy-proven or clinical evidence of renal disease:Biopsy-proven disease:Living subjects with unconfirmed but suspected renal disease or deceased subject with
“nephritis” noted on their death certificates
bFamily members for which renal status was known from biopsy, urinary abnormalities consistent with glomerulonephritis, or history of renal disease
cPredominant immunoglobulin associated with mesangioproliferative glomerulonephritis in the absence of IgA deposits is indicated. Abbreviations are: FSGS,
focal segmental glomerulosclerosis; DM, diabetic changes; MGN, membranous glomerulonephropathy; GN, glomerulosclerosis
dAnalysis included all patients with biopsy-proven, clinical evidence of renal disease, and suspected but unconfirmed renal disease
ated with severe clinical disease and a generally poor this “syndrome” of renal disease exists is most evident
in F-V, in which 10 of 31 patients underwent renal biopsy,outcome [91]. All three cases presented with nephrotic
range proteinuria. Two progressed to ESRD, and one the biopsy findings were variable, but segregation of the
disease trait fits a simple autosomal dominant inheri-patient had three family members with IgA-predominant
mesGN. The variability of IF findings in the reported tance pattern (Table 4).
In the case of a large five-generation Australian Ab-Zuni families may be explained if this variant of familial
renal disease manifests early as IF-negative or isolated original kindred exhibiting clustering of IgAN, the pat-
tern of inheritance is uncertain. Table 4 summarizes theIgM deposition disease, with IgA, IgG, and complement
deposition variably superimposed later by Ig class switch- original pedigree consisting of a father with biopsy-proven
IgAN and a history of significant alcohol use (.160 g/day)ing in response to provoking antigenic stimuli. The ap-
pearance or disappearance of IgA in sequential biopsies but no overt liver disease, a mother with renal disease but
biopsy findings more consistent with chronic ischemicof several subjects has been noted [88, 91]. While mesan-
gial IgA deposits have rarely been reported to decrease changes and diabetic nephropathy, and eight children
(3 biopsy-proven IgAN, 1 biopsy-proven IgA-negativeor disappear in serial renal biopsies in patients with pIgAN
[138, 139], the appearance of mesangial IgA deposits mesGN) and seven grandchildren with hematuria [94].
Both parents and two of their children had type 2 diabe-in a second renal biopsy specimen has been previously
reported for several patients presenting with proteinuria tes mellitus, but the children had biopsy-proven IgAN.
The marked male predominance (only 2 affected daugh-and hematuria in whom the initial biopsy failed to detect
IgA deposits [140, 141]. The additional finding of isolated ters) suggests an X-linked recessive inheritance pattern
[87]. However, for this to be the case, the mother (whoFSGS and MPGN among members of Zuni families af-
fected predominantly with mesGN raises the possibility had no biopsy evidence of IgAN) would have to be an
asymptomatic carrier of one X-linked disease allele forthat other genetic and/or environmental etiologic factors,
distinct from those responsible for familial IgAN with IgAN. The father was subsequently found to be the patri-
arch of a branch of the third generation of a five-genera-the typical clinical features of pIgAN, are involved in
the pathogenesis of familial renal glomerular disease tion extended pedigree. All seven affected members in
the fifth generation who were diagnosed with hematuriaamong the Zuni Indians. That a strong genetic basis for
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Table 5. Familial syndromes with associated IgAN
Other affected Putative mode
Ref. Year Syndrome Relationship of affected probands Race Ethnicity family membersa of inheritance
[90] 1984 Overlapping IgA and Brothers Caucasian American ND ?
membranous GN
[91] 1988 Spastic paraplegia, Mother with a son and a son-daughter Caucasian British Grandmother and ?
bilat. sensorineural sib pair from 2 marriages grandaunt of
hearing loss, mental affected sibs
retardation, and IgAN and half-sibs
[92] 1992 Bilat. sensorineural Brother-sister sib pair and a son and Caucasian Spanish Hearing loss in 1st Autosomal
hearing loss and IgAN a daughter of the brother two generations; dominant
urine not examined
[93] 1989 HSP and IgAN Mother and two daughters Asian Japanese Maternal grandmother ?
with proteinuria
[86] 1989 HSP and IgAN 19 families (2–4 affecteds): 13 with two Caucasian French Various ?
1st degree relatives; 1 with two 2nd Algerian
degree relatives; 5 with multigenera- Moroccon
tional affecteds Madagascar
[79] 1990 HSP and IgAN Father and son Caucasian Spanish ND ?
[94] 1998 Thin basement Three sisters Asian Japanese Father with ?
membrane and IgAN hematuria, nl bx.
aDisease status of family members determined by screening urinalysis
were #10 years of age. The pattern of disease segregation as the etiology of disease in that family. However, neither
the high rate of alcohol intake nor prevalence of diabetesin the additional affected members did not clearly follow
any readily identifiable pattern of inheritance. mellitus among the Zuni Indians and the Australian Ab-
originals can explain the observed clustering of IgAN inAt least a subset of pIgAN families (F-I, F-II, and
F-IV; Table 4) with ancestral clustering from the isolated the remaining families, since nonalcoholic and nondia-
betic family members (especially children) were oftenValsaviore valley of the district of Brescia in Northern
Italy also exhibited a male predominance among affected affected. In addition, the age of onset (age at biopsy
varied over the range of 1 to 66 years in the Zuni families;members and appear to exhibit an X-linked recessive
trait [42]. Ancestral clustering of birthplace in this subset age at diagnosis varied over the range of 5 to 76 years
in the Italian families) and the time intervals separatingof Valsaviore families is also consistent with a genetic
“founder” effect [42]. F-V through F-IX are two-genera- the apparent onset of disease (8 months to 13 years in
the Italian families), which varied widely among familytional families with a predominance of affected males
but without a sufficient number of family members to members, are not consistent with the effects of a common
environmental exposure [42, 88, 94].suggest clearly a discrete pattern of inheritance. How-
ever, F-VII and F-VIII exhibit father-to-son transmis- Finally, a Japanese case-control study of risk factors
for IgAN, with patient characteristics regarding educa-sions, which would exclude X-linked recessive inheritance
in these families (although matings of a carrier female tional level, food intake, frequency of respiratory infec-
tions (colds), exposure to solvents, and family history ofand an affected male can give the appearance of male-
to-male transmission) [87]. Nonetheless, the apparent “chronic GN” obtained through a questionnaire, found
modestly increased or decreased ORs for various envi-X-linked recessive mode of inheritance in F-I, F-II, and
F-IV suggests that the putative disease locus is distinct ronmental exposures (range 0.42 to 4.73) when univari-
ate analysis was performed. However, a family historyfrom those segregating in the Kentucky and Zuni families.
A common environmental exposure was not identified of “chronic GN” in a parent, first-degree relative, or
first- and second-degree relatives had an OR of 16 (95%in any of these reported familial clusterings of IgAN or
IgA-associated mesGN in the case of the Zuni Indians. CI, 2 to 128), 6.67 (95% CI, 1.84 to 24.2), and 4.8 (95%
CI, 1.69 to 13.6), respectively, for the increased risk ofSince not all family members were affected, phenotypic
expression of disease caused by exposure to a presump- developing biopsy-proven IgAN [19]. Despite inherent
weaknesses in this type of study, including recall bias,tive environmental stimulus could arise only as a result
of epistatic effects on a disease susceptibility gene. Alco- differences in exposure ascertainment among cases and
controls, selection bias caused by healthier controls, in-holic liver disease has been reported to be associated
with secondary mesGN with IgA and IgM deposits on creased a error secondary to multiple comparisons, and
the absence of multivariate analysis to identify indepen-renal biopsy [95]. Indeed, both biopsy-proven cases of
IgAN in F-IV had concomitant alcoholic liver disease, dent risk factors, the robust OR for family history of
“chronic GN” argues strongly for a genetic componentsuggesting secondary IgAN rather than familial IgAN
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in the pathogenesis of biopsy-proven pIgAN among Jap- strain [105] and the mink affected with Aleutian disease
[106]. In addition, the pathologic features of IgAN haveanese.
recently been reported in the UG knockout mouse and
Familial overlap syndromes with associated IgAN UG antisense transgenic mouse models [142]. We review
the pathologic, immunologic, and immunogenetic char-The study of overlap syndromes has the potential to
provide clues regarding disease-associated genetic loci acterization of hereditary IgAN in the ddY and UG-
deficient mouse models.when a consistent chromosomal abnormality results in
the loss of multiple contiguous genes and gives rise to a
Spontaneous IgAN in the ddY mousecomplex clinical phenotype. Often, these chromosomal
abnormalities are cytogenetically detectable as deletions, Imai et al reported that ddY mice derived from nonin-
bred dd-stock mice known to carry a retrovirus causingtranslocations, monosomies, or polysomies. A paradigm
for this type of contiguous disease genes locus is the mammary gland tumors developed spontaneous IgA-
predominant mesangial deposits [105]. A 59-week naturalWAGR region, encoding at least three genes (WT1,
AN2, and 239FB), which are mutated or deleted in the history study of the clinical phenotype and renal pathol-
ogy of these animals revealed many of the hallmarks ofsyndrome of Wilms’ tumor, aniridia, genitourinary ab-
normalities, and mental retardation [96–99]. classic pIgAN in humans. Mild to moderate albuminuria
was detectable after 28 weeks and increased progres-IgAN has been reported as a familial overlap syn-
drome in a single family with associated bilateral sensori- sively with age. Mesangial cell proliferation became evi-
dent at 16 weeks and progressed to overt mesangioproli-neural hearing loss that is distinguishable from Alport
syndrome (Table 5) [100]. This four-generation Spanish ferative GN by 59 weeks. IgG and IgM mesangial
deposition was predominant until 28 weeks, whereas IgAfamily has three members in the last two generations
with bilateral sensorineural hearing loss and microscopic deposition became predominant at 40 weeks and per-
sisted at 59 weeks. Serum polyclonal IgA in ddY micehematuria; two had biopsy-proven IgAN. All four gener-
increased by 850% at 59 weeks. Serum creatinine in 48-ations have affected members with a history of hearing
week-old ddY mice was approximately 2.5-fold higherloss, but renal disease status was not ascertained for the
than 6-week-old ddY mice [107]. No antinuclear antibod-majority of family members, as few were screened for
ies were detected, and amyloid staining was negativeurinary abnormalities. Both hearing loss and nephritis
[105]. ddY mice have IgG antihistone autoantibodiesappear to segregate in an autosomal dominant fashion
that react with proteins extracted from renal tissue thatin this family. Genes for autosomal dominant (DFNA11)
have been identified as histones H3 and H1 [108]. Theand recessive (DFNB2) nonsydromic sensorineural deaf-
pattern of early mesangial proliferative changes, withness have been mapped to chromosome 11q12.3-q21
subsequent development of mesangial deposits consisting[101], while a nonsyndromic X-linked form of sensori-
predominantly of IgA with associated massive accumula-neural deafness (DFN4) has been mapped to Xp21.2
tion of electron dense materials in the mesangium and[102]. These loci may represent candidate regions con-
subendothelial space and the development of azotemia,taining IgAN disease/susceptibility genes. An additional
mimics the morphological and clinical features of humanfamily with the syndrome of spastic paraplegia, bilateral
IgA nephritis. Hematuria, however, was noticeably ab-sensorineural deafness, mental retardation, and IgAN
sent. Although ddY mice have been reported to develophas also been reported [103]. However, linkage studies
mammary gland tumors at the age of 40 weeks, whichof genes implicated in various forms of syndromic and
coincides with the onset of high serum polyclonal IgAnonsyndromic spastic paraplegia, sensorineural deaf-
levels, none of the animals sacrificed at 59 weeks exhib-ness, and mental retardation do not indicate a common
ited mammary tumor formation or any other kinds ofchromosomal region of clustered known disease genes
tumors. Thus, the mammary gland is unlikely to be thethat could explain this constellation of clinical findings
source of IgA overproduction in ddY mice.[101, 102, 104].
Noting that the incidence of mesangioproliferative
IgAN in the ddY strain was not very high (approximately
ANIMAL MODELS OF IgAN 10%), likely because of its heterogeneous genetic back-
The spontaneous development of glomerular or tubu- ground as derived from outbred dd-stock mice, Miya-
lar disease in certain strains of mice and rats has provided waki et al isolated a strain of ddY mice designated HIGA
useful models for the study of the pathogenesis, molecu- (“high IgA”) by selective breeding of individual ddY
lar genetics, and response to experimental therapy of mice with the highest serum IgA levels [109]. The re-
important renal diseases such as diabetic nephropathy, sulting strain, maintained as brother-sister matings after
hypertensive nephropathy, polycystic kidney disease, F2, is characterized by mean IgA levels at four months
and lupus nephritis. Two animal models of spontaneous of age that are nine and five times that of the founders
in females and males, respectively. Approximately 50%IgA nephritis have been reported to date: the ddY mouse
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of HIGA mice exhibit evidence of early onset (at 25 tion, but not the level of serum IgA production. Consis-
tent with this hypothesis, the administration of a mono-weeks) moderate to severe mesangial IgA deposition,
and more than 70% show moderate to severe mesangio- clonal antibody to murine CD4 molecules resulted in
selective reduction in the number of CD41 T cells andproliferative GN and massive matrix expansion at 40
weeks. The latter was associated with a high incidence a decrease in IgA mesangial deposition, but no difference
in the levels of serum IgA, urinary protein, or averageof global glomerulosclerosis in aged mice, a rare finding
in the original ddY strain. Such lesions would be ex- number of intraglomerular cells between treated and
control ddY mice [115]. In contrast, treatment with anti-pected to lead to a more marked decline in renal func-
tion. However, assessment of renal function was not re- CD8 monoclonal antibody resulted in a reduction in
mesangial hypertrophy in ddY mice, but had no effectported in this study. Notably, the HIGA mice manifested
only mild proteinuria (at most 300 mg/dL) and no hema- on proteinuria or serum IgA levels [116]. These results
suggest that while CD41 T cells mediate mesangial depo-turia. Approximately 25% of the HIGA mice had only
a mild IgA mesangial deposition at 60 weeks of age, and sition of IgA, CD81 T cells mediate mesangial prolifera-
tion and disease progression in ddY mice.serum IgA levels varied widely even after four genera-
tions of selection. The relative contribution of genetic Nagasawa et al have documented a unique TCR g
chain in ddY mice by RFLP analysis [117]. Since T cellsfactors to the variation in serum IgA levels was estimated
to be about 40% [109]. These findings suggest that persis- bearing TCR g chain are highly represented in tonsillar
and gut-associated lymphoreticular tissues indispensibletent genetic or environmental heterogeneity contributes
to the development of IgAN in HIGA mice. Indeed, for IgA production, a TCR c polymorphism could under-
lie abnormal T-cell–regulated IgA production in theseboth ddY and HIGA mice, like many other strains of
experimental mice, are known to harbor retroviral infec- tissues. TCR c polymorphisms have not yet been exam-
ined in human IgAN.tions. Takeuchi et al have documented increased mesan-
gial deposition of immune complexes containing retrovi- The disappearance of mesangial IgA deposits after
allogeneic bone marrow transplantation in a patient withral envelope antigen gp70 in ddY in an age-dependent
manner in mice over 24 weeks old, in parallel with the IgAN and chronic myelogenous leukemia prompted Im-
asawa et al to investigate a role for hematopoietic stemextent of IgA and IgG mesangial deposition [110]. In
contrast, no gp70 deposits were observed in 12-week- cells in the pathogenesis of IgAN. T-cell–depleted bone
marrow cells from ddY mice were transplanted intoold mice without mesangioproliferative GN.
C57BL/6j (B6) mice pretreated with cyclophosphamide.
Immunopathology and immunogenetics of IgAN in B6 recipients of T-cell–depleted allogeneic bone marrow
the ddY mouse cells from ddY mice exhibited significantly higher serum
IgA levels, higher relative proportions of polymeric IgA,Serum IgA levels and the polyclonal IgA response of
lymphocytes isolated from Peyer’s patches (but not from and more intense mesangial IgA and C3 deposits com-
pared with B6 mice receiving syngeneic bone marrowspleen) are significantly higher in ddY mice with glomer-
ular IgA deposits [111]. These immunologic studies sug- cells from B6 mice [118]. Allogeneic bone marrow trans-
plants from normal mice to ddY mice resulted in de-gest that gut-associated lymphoreticular tissue plays an
important role in the pathogenesis of high IgA serum creased serum levels of polymeric IgA and amelioration
of nephritis. These results suggest that aberrant serumresponse and glomerular IgA deposition in ddY mice.
Selective glomerular deposition of more acidic IgA mole- IgA production in ddY mice is quantitatively and qualita-
tively determined by signals originating from bone mar-cules among the polyclonally expanded IgA has also been
observed in old ddY mice [112]. In addition, the severity row stem cells.
of GN is associated with a predominance of the poly-
Role of cytokines that stimulate mesangial cellmeric form of serum IgA. This is consistent with the
proliferation and extracellular matrix deposition in thefinding that IgA eluted from the kidneys of patients with
pathogenesis of IgAN in the ddY mouseIgAN is predominantly polymeric and anionic (pI 5 4.5
to 6.8) [113]. Platelet-derived growth factor (PDGF), transforming
growth factor-b (TGF-b), IL-1, IL-6, IL-6 receptorEvidence for the role of aberrant cell-mediated immu-
nity in the pathogenesis of IgAN in ddY mice includes (IL-6R), and the endothelins (ETs) have been implicated
in the mitogenic and fibrogenic response leading to mes-a significant reduction in mesangial IgA deposition fol-
lowing removal of thymus-derived T cells by neonatal angial cell proliferation and accumulation of extracellu-
lar matrix (ECM) in IgAN and other glomerulopathiesthymectomy [114]. Since serum IgA levels and the rela-
tive proportion of serum polymeric IgA in thymecto- [119–123]. In ddY mice, PDGF-A chain and PDGF-B
chain messenger RNA (mRNA) levels increase progres-mized animals were not different from control animals,
hypofunction of thymus-derived T cells appears to play sively in an age-dependent fashion and are 2.2-fold and
2.4-fold higher at 48 weeks compared with New Zealanda role in determining the extent of mesangial IgA deposi-
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White (NZW) control mice (P , 0.05) [124]; this increase ddY mice compared with age-matched ICR control mice
(P , 0.01 for all outcomes) [122]. Treatment of 24-week-is paralleled by a twofold increase in proliferating cell
nuclear antigen (PCNA) mRNA, a marker of cell prolif- old ddY mice (prior to onset of histologic evidence of
IgAN) for 36 weeks with the ET receptor A antagonisteration. Similarly, TGF-b1 and TGF-b2 mRNA levels
increase in an age-dependent manner and are signifi- FR 139317 resulted in a significant attenuation of protein-
uria, a reduction in renal impairment, and a reduction ofcantly higher in ddY mice with nephropathy compared
with their littermates without nephropathy [125]. Fur- mesangial hypercellularity compared with age-matched
saline-treated ddY mice (P , 0.01) and ICR controlthermore, TGF-b2 mRNA levels correlate positively
with the mesangial matrix expansion index (P , 0.05), mice (P , 0.05). Thus, ET family members also appear
to play an important pathogenic role in the establishedraising the possibility that TGF-b2 may be an important
mediator of ECM production in the mesangioprolifera- phase of IgAN in ddY mice.
tive IgAN affecting ddY mice.
Uteroglobin-deficient mouse modelsMessenger RNA transcripts encoding ECM compo-
nents such as type I and type IV collagen a1 chains, A recent series of reports describing two independent
genetic models of uteroglobin (UG) deficiency has unex-laminin A, B1, and B2 chains, fibronectin (FN), and
heparan sulfate proteoglycan (HSPG) have also been pectedly revealed a novel role for this cytokine-like se-
cretory protein in the prevention of IgAN in mice [142,reported to be up-regulated in ddY mice compared with
age-matched control animals, in parallel with the extent 143]. Both UG2/2 and UG1/2 knockout mice were origi-
nally reported to manifest abnormal glomerular deposi-of IgA and C3 mesangial deposition [126, 127]. However,
only TGF-b, type 4 collagen a1 chains, FN, and HSPG tion of FN and collagen, leading to renal failure [143].
Subsequently, both the UG gene-disrupted mice and twohave been demonstrated by IF to be components of the
increased mesangial matrix of ddY mice [128] and HIGA independent lines of UG-antisense transgenic (AS-UG)
mice were found to have high circulating levels of IgA-mice [127]. Given the likely selection of “high secretor”
IgA-bearing B-cell clones and evidence of increased mes- FN complexes and abnormal glomerular deposits of IgA
(massive in the case of UG2/2 mice), FN, collagen, andangial ECM production in HIGA mice, Muso et al have
speculated that these phenomena may both be related C3. In addition to these features, which closely mimic
the histopathologic findings in human pIgAN, UG2/2to the observed local up-regulation of TGF-b in the
mesangium. TGF-b may play a prominent role in pro- animals developed significant microhematuria (.200 red
blood cells per high-power field) and massive proteinuriamoting ECM production while also acting as an immuno-
regulatory cytokine in inducing the IgA isotype switching [142, 143]. Notably, UG was shown to prevent both the
formation of IgA-FN complexes in vitro and the glomer-of mature IgA-producing B cells and in suppressing IgG
and IgM secretion [127]. ular deposition of exogenously administered IgA in vivo.
Thus, in mice, UG plays an essential role in preventingNephritogenic IgA-immune complexes (IC) have
been shown to activate human mesangial cells to produce the abnormal glomerular accumulation of IgA [142]. The
role of UG in the prevention of human pIgAN remainscytokines such as IL-1 and IL-6 [129]. The role of IL-1
in the progression of established IgAN in ddY mice was to be determined.
investigated by administration of IL-1 receptor antago-
Limitations of murine models of IgANnist (IL-1ra), an 18 kD glycoprotein with homology to
both IL-1a and IL-1b, that competitively inhibits the Although study of the ddY and the UG-deficient
mouse models may provide important clues about theeffects of IL-1 receptor in vivo [107]. Forty-week-old
ddY mice treated weekly for two months showed reduc- pathogenesis of human pIgAN, several potentially im-
portant phenotypic differences between murine IgANtions in proteinuria, serum creatinine, mesangial cell pro-
liferation, and glomerular expression of collagen type in these models and human pIgAN may limit the ability
to infer mechanisms derived from studies of the former,IV, FN, laminin, IL-6, as well as decreased glomerular
C3 deposition compared with age-matched saline- to pathogenesis of disease in the latter. The ddY and
HIGA mice exhibit an absence of hematuria and demon-treated ddY mice (P , 0.001 for all outcomes). Thus,
IL-1 appears to play a key pathogenic role in the estab- strate only modest proteinuria [105]. In addition, humans
have two IgA subclasses (IgA1 and IgA2), while micelished phase of IgAN in ddY mice.
Endothelins may contribute to the progression of glo- have only one IgA subclass. In human pIgAN, the IgA
deposited in the mesangium is almost exclusively IgA1,merular disease either by inducing local vasoconstriction
or by stimulatory effects on mesangial cell proliferation with only infrequent and low-level deposition of IgA2
[140]. In contrast to IgG, IgM, and IgA2, the humanand overproduction of ECM components [130, 131]. Sig-
nificantly increased mRNA levels of renal ET-1 (6.6- IgA1 isotype contains a unique hinge region between
the CH1 and CH2 domains of the a1 heavy chain. Recentfold) and ET receptor A (4.8-fold), and B (3.6-fold), but
not ET-3, were observed from 8 to 60 weeks of age in studies have demonstrated that circulating immune com-
Hsu et al: Genetic factors in IgA nephropathy 1831
plexes isolated from the sera of IgAN patients are com- alcohol abuse among the Zuni Indians and Australian
Aboriginals, that may contribute to or modify pheno-posed of aberrantly undergalactosylated O-linked gly-
cans in the hinge region and increased amounts of IgG typic expression of an inherited disease trait. Sib pair
analysis [136], affected relative pair analysis [137], and(and less frequently, naturally occurring IgA1) directed
at such galactose-deficient antigenic determinants, as the transmission/dysequilibrium test (TDT) [146] have
also been successfully applied when the underlying ge-compared with healthy controls [144, 145]. The forma-
tion of these immune complexes has been hypothesized netic model is not evident. Such nonparametric models
take advantage of the simplicity of family structure andto interfere with the hepatic clearance of abnormal IgA1
molecules, leading to their accumulation in the serum well-developed statistical methodologies. Candidate gene
approaches looking at polymorphisms of putative dis-and eventual deposition in the glomerulus [144, 145].
Since the single IgA isotype in mice lacks a hinge region, ease genes or markers in linkage disequilibrium with
disease genes are also best conducted in the setting ofno existing murine model can explain this proposed
mechanism of human IgA1-mediated glomerulopathy. family based studies such as the TDT. Unlike population-
based studies such as the case-control comparison, whichNonetheless, since human pIgAN is likely to be a geneti-
cally heterogeneous entity and not all patients with can give rise to spurious associations caused by popula-
tion stratification (the existence of multiple populationpIgAN have abnormally O-glycosylated IgA1, ddY and
UG-deficient mice may prove to be useful models for subtypes), the TDT considers parents who are heterozy-
gous for an allele associated with disease and evaluatesthe study of alternative mechanisms of IgA-associated
glomerular disease. the transmission of that allele to a single affected off-
spring [146]. The TDT can be a more powerful test to
detect linkage than the affected sib pair linkage tests,
APPROACHES TO THE IDENTIFICATION OF
particularly for disease alleles that contribute small ge-
IgAN DISEASE/SUSCEPTIBILITY GENES
netic effects.
Evidence derived from the study of the immunogenet- Finally, the ddY and HIGA mouse models of sponta-
ics, racial differences in prevalence, and familial occur- neous IgAN and the UG-deficient mouse models have
rence of IgAN, as well as the existence of a mouse model yielded a large body of information with possible rele-
of spontaneous IgAN, strongly supports the influence of vance to both the immunology and immunogenetics of
genetic factors in the development and progression of human IgAN and suggest experimental therapeutic mo-
the IgA glomerulopathies. This evidence also suggests dalities that deserve further investigation in human clini-
a number of feasible approaches for the identification cal trials. The role of UG deficiency in the development
and positional cloning of putative IgAN disease/suscepti- of IgAN in mice has been convincingly demonstrated,
bility genes. Case-control studies are inherently limited but requires confirmation as a mechanism of human dis-
in their ability to prove an association between a candi- ease. Identification and positional cloning of disease/
date gene and the development or progression of IgAN. susceptibility loci in the ddY and HIGA mouse models
Given the successful efforts of a number of investigators have not been reported to date. The outbred nature of
to obtain clinical samples from members of IgAN multi- the ddY mouse strain lends itself to such an analysis.
plex families, along with powerful new molecular genetic We speculate that genetic analysis of the ddY mouse
tools and statistical methods for gene mapping of both will reveal a gene(s) responsible for the development of
Mendelian and complex genetic disease traits, we pro- IgAN, while analysis of both the ddY and HIGA mice
pose that genetic analysis of familial IgAN is the most will provide insight into the genes that mediate progres-
promising approach to the identification of IgAN dis- sion of established disease. Such genes likely function
ease/susceptibility genes. upstream of the regulatory pathway(s) leading to overex-
Recent success with linkage mapping of independent pression of such immunoregulatory growth factors and
disease genes causing familial FSGS provides a paradigm cytokines as PDGF, TGF-b, IL-1, and ET, which have
for such an approach [132–134]. These studies demon- been shown to mediate the glomerular abnormalities
strate the feasibility of disease gene mapping of Mende- characteristic of IgAN in both humans and the ddY
lian traits in single large kindreds. Genetic heterogeneity mouse.
is unlikely to be a confounder in the analysis of individual
large kindreds or closely related families assumed to
POSTSCRIPThave a Mendelian disease. In the absence of readily iden-
tifiable patterns of inheritance characteristic of complex We are a group of clinical and molecular epidemiolo-
gists, geneticists, and molecular nephrologists who arehuman diseases, genetic epidemiologic methods [135]
employing stringent, conservative clinical classification actively recruiting families with familial IgAN in Singa-
pore and the United States for the purpose of gene map-schemes can be used to analyze polygenic interactions
as well as the effect of environmental factors such as ping of IgAN disease/susceptibility genes. We invite phy-
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